Russell Clayton - 17 Jul 2023 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
Chief Medical Officer
Signature
/s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol
LRMR
Transactions as of
17 Jul 2023
Net transactions value
$0
Form type
4
Filing time
18 Jul 2023, 16:15:06 UTC
Next filing
19 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +180,000 $0.000000 180,000 17 Jul 2023 Common Stock 180,000 $3.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests 25% on July 17, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.